| abstract |
Disclosed is a cancer reduction effect at a site far from an administered cancer (for example, a cancer transplanted on the other side of the body) and suppression of metastasis (lymph node metastasis) via a lymphatic system leading to a cancer tumor. Provision of a therapeutic composition for cancer having an effect. A therapeutic composition for cancer used for lysis of metastatic cancer, comprising a complex containing Sendai virus genomic RNA, wherein the nucleic acid encoding M protein is mutated or deleted. And a genomic RNA encoding a protein that is a modified F protein, wherein the sequence of the cleavage site of the protein is replaced by a sequence that is cleaved by a protease that does not cleave the wild type F protein, and the wild type of Sendai virus Further comprising F protein, the complex promotes metastasis from the tumor to lymph nodes, growth of distant metastatic cancer, and degeneration of lymph node metastasis by intratumoral administration. [Selection] Figure 2 |